Striatal response to reward anticipation evidence for a systems-level intermediate phenotype for schizophrenia

JAMA Psychiatry

Volumn 71, Issue 5, 2014, Pages 531-539

  Grimm, Oliver ^a   Heinz, Andreas ^a   Walter, Henrik ^a   Kirsch, Peter ^a   Erk, Susanne ^a   Haddad, Leila ^a   Plichta, Michael M ^a   Romanczuk Seiferth, Nina ^a   Pöhland, Lydia ^a   Mohnke, Sebastian ^a   Muhleisen, Thomas W ^a   Mattheisen, Manuel ^a   Witt, Stephanie H ^a   Schäfer, Axel ^a   Cichon, Sven ^a   N̈then, Markus ^a   Rietschel, Marcella ^a   Tost, Heike ^a   Meyer Lindenberg, Andreas ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ADULT; ANTICIPATION; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; BRAIN SIZE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FIRST DEGREE RELATIVE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENOTYPE; GRAY MATTER; HUMAN; MALE; MISSENSE MUTATION; NORMAL HUMAN; PHENOTYPE; REWARD; REWARD ANTICIPATION; SCHIZOPHRENIA; TEST RETEST RELIABILITY; VOXEL BASED MORPHOMETRY;

ADULT; ANTICIPATION, PSYCHOLOGICAL; BASAL GANGLIA; BRAIN; BRAIN MAPPING; DOPAMINE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTIVATION; MUTATION, MISSENSE; NEUREGULIN-1; PHENOTYPE; REFERENCE VALUES; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84900436429     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.9     Document Type: Article

References (51)

1. Plichta MM, Schwarz AJ, Grimm O, et al. Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery. Neuroimage. 2012;60(3):1746-1758.
2. Kirsch P, Schienle A, Stark R, et al. Anticipation of reward in a nonaversive differential conditioning paradigm and the brain reward system: an event-related fMRI study. Neuroimage. 2003;20(2):1086-1095.
3. Juckel G, Schlagenhauf F, KoslowskiM, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29(2):409-416.
4. Nielsen MO, Rostrup E,Wulff S, et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry. 2012;69(12):1195-1204.
5. Esslinger C, Englisch S, Inta D, et al. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res. 2012;140(1-3):114-121.
6. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl). 2006;187(2):222-228.
7. Fusar-Poli P,Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-Analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull. 2013;39(1):33-42.
8. Miyake N, Thompson J, SkinbjergM, Abi-Dargham A. Presynaptic dopamine in schizophrenia. CNS Neurosci Ther. 2011;17(2):104-109.
9. Fusar-Poli P,Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: meta-Analysis of dopamine active transporter (DAT) density. Schizophr Bull. 2013;39(1):22-32.
10. Schott BH, Minuzzi L, Krebs RM, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci. 2008;28(52):14311-14319.
11. Goldman AL, Pezawas L, Mattay VS, et al. Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry. 2008;63(5):475-483.
12. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23.
13. Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia- psychopathological and behavioral correlates. Eur Psychiatry. 2002;17(1):9-16.
14. Juckel G, Friedel E, Koslowski M, et al. Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology. 2012;66(1):50-56.
15. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35(3):549-562.
16. Dreher JC, Kohn P, Kolachana B,Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A. 2009;106(2): 617-622.
17. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636-645.
18. Kendler KS, Gruenberg AM, TsuangMT. Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients: a family study using DSM-III criteria. Arch Gen Psychiatry. 1985;42(8):770-779.
19. Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS,Weinberger DR. Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry. 2011;68(12):1207-1217.
20. Callicott JH, Egan MF, Mattay VS, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry. 2003;160(4):709-719.
21. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry. 2008;63(1):114-117.
22. Esslinger C, Kirsch P, Haddad L, et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage. 2011;54(3):2514-2523.
23. Ballmaier M, Schlagenhauf F, Toga AW, et al. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophr Res. 2008;106(2-3): 140-147.
24. Glenthoj A, Glenthoj BY, Mackeprang T, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 2007;154(3):199-208.
25. LiM, Chen Z, DengW, et al. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. Psychol Med. 2012;42(7):1475-1483.
26. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4): 877-892.
27. Law AJ, Lipska BK,Weickert CS, et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associatedwith the disease.ProcNatl AcadSci U S A. 2006;103(17):6747-6752.
28. Zheng Y,Watakabe A, Takada M, et al. Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):701-706.
29. Fox IJ, Kornblum HI. Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. J Neurosci Res. 2005;79(5):584-597.
30. Kato T, Abe Y, Sotoyama H, et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry. 2011;16(3):307-320.
31. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-Analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827-834.
32. Corrigan JD, Hinkeldey NS. Relationships between parts A and B of the 3611374. J Clin Psychol. 1987;43(4):402-409.
33. Schlagenhauf F, Sterzer P, Schmack K, et al. Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry. 2009;65(12):1032-1039.
34. Bennett CM, Miller MB. How reliable are the results from functional magnetic resonance imaging? Ann N Y Acad Sci. 2010;1191:133-155.
35. Grimm O, Vollstadt-Klein S, Krebs L, Zink M, Smolka MN. Reduced striatal activation during reward anticipation due to appetite-provoking cues in chronic schizophrenia: a fMRI study. Schizophr Res. 2012;134(2-3):151-157.
36. Zink CF, Pagnoni G, Martin-Skurski ME, Chappelow JC, Berns GS. Human striatal responses to monetary reward depend on saliency. Neuron. 2004;42(3):509-517.
37. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci. 2001;21(16):RC159.
38. Simon JJ, Biller A,Walther S, et al. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr Res. 2010;118(1-3):154-161.
39. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420-428.
40. Meyer-Lindenberg A. Intermediate or brainless phenotypes for psychiatric research? Psychol Med. 2010;40(7):1057-1062.
41. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13-20.
42. Sanchez-Torres AM, Basterra V, Moreno-Izco L, et al. Executive functioning in schizophrenia spectrum disorder patients and their unaffected siblings: a ten-year follow-up study. Schizophr Res. 2013;143(2-3):291-296.
43. Vernaleken I, Buchholz HG, Kumakura Y, et al. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp. 2007;28(10): 931-939.
44. Kellendonk C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49(4):603-615.
45. Tan HY, Chen AG, Kolachana B, et al. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain. 2012;135(pt 5):1436-1445.
46. Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry. 2013;74(2):122-129.
47. Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1-39.
48. Meyer-Lindenberg A,Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267-271.
49. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III, a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry. 1988;45(7):609-615.
50. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect. 1993;91(2-3):111-134.
51. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry. 2010;67(7):683-691.